Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Metformin | 9 | 2025 | 134 | 3.460 |
Why?
|
| Ovarian Neoplasms | 19 | 2025 | 826 | 3.320 |
Why?
|
| Calcium, Dietary | 5 | 2025 | 69 | 1.490 |
Why?
|
| Gynecology | 3 | 2025 | 135 | 1.430 |
Why?
|
| Obstetrics | 3 | 2025 | 125 | 1.430 |
Why?
|
| Culturally Competent Care | 2 | 2017 | 14 | 1.060 |
Why?
|
| Hypoglycemic Agents | 5 | 2019 | 416 | 0.880 |
Why?
|
| Prenatal Care | 1 | 2025 | 81 | 0.880 |
Why?
|
| Dietary Supplements | 1 | 2025 | 152 | 0.840 |
Why?
|
| Physicians, Women | 1 | 2025 | 66 | 0.840 |
Why?
|
| Calcium | 3 | 2025 | 1198 | 0.800 |
Why?
|
| Sexual and Gender Minorities | 2 | 2017 | 262 | 0.790 |
Why?
|
| Pre-Eclampsia | 1 | 2025 | 270 | 0.730 |
Why?
|
| BRCA1 Protein | 2 | 2018 | 222 | 0.580 |
Why?
|
| Glycolysis | 2 | 2017 | 198 | 0.570 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 64 | 0.570 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2016 | 69 | 0.550 |
Why?
|
| Food, Fortified | 3 | 2024 | 18 | 0.540 |
Why?
|
| Maternal Health Services | 1 | 2017 | 16 | 0.530 |
Why?
|
| Marriage | 1 | 2017 | 23 | 0.530 |
Why?
|
| Fertilization in Vitro | 1 | 2017 | 55 | 0.530 |
Why?
|
| Homosexuality, Female | 1 | 2017 | 17 | 0.530 |
Why?
|
| Spouses | 1 | 2017 | 32 | 0.520 |
Why?
|
| Female | 33 | 2025 | 51533 | 0.490 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 79 | 0.480 |
Why?
|
| Carcinosarcoma | 1 | 2016 | 31 | 0.460 |
Why?
|
| Epithelial Cells | 2 | 2017 | 710 | 0.460 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2016 | 64 | 0.450 |
Why?
|
| Tumor Microenvironment | 3 | 2019 | 618 | 0.440 |
Why?
|
| Parents | 1 | 2017 | 322 | 0.420 |
Why?
|
| Hyperglycemia | 1 | 2015 | 187 | 0.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 2658 | 0.410 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 93 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2015 | 1394 | 0.390 |
Why?
|
| Cell Line, Tumor | 10 | 2020 | 2892 | 0.390 |
Why?
|
| Genital Neoplasms, Female | 1 | 2014 | 118 | 0.380 |
Why?
|
| Flour | 2 | 2024 | 4 | 0.380 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 479 | 0.370 |
Why?
|
| Endometrial Neoplasms | 1 | 2016 | 242 | 0.370 |
Why?
|
| Paclitaxel | 1 | 2014 | 483 | 0.370 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 2374 | 0.370 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2013 | 461 | 0.370 |
Why?
|
| Humans | 36 | 2025 | 97979 | 0.360 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2011 | 34 | 0.350 |
Why?
|
| Estradiol | 1 | 2011 | 268 | 0.320 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 405 | 0.320 |
Why?
|
| Adipocytes | 3 | 2020 | 180 | 0.310 |
Why?
|
| Contraceptives, Oral, Synthetic | 1 | 2009 | 6 | 0.300 |
Why?
|
| Ethinyl Estradiol | 1 | 2009 | 16 | 0.300 |
Why?
|
| Norethindrone | 1 | 2009 | 13 | 0.300 |
Why?
|
| Indoles | 1 | 2011 | 334 | 0.300 |
Why?
|
| Pregnancy | 5 | 2025 | 3266 | 0.300 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2009 | 100 | 0.290 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 1536 | 0.280 |
Why?
|
| Vacuum Curettage | 1 | 2007 | 5 | 0.270 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2019 | 176 | 0.270 |
Why?
|
| Tramadol | 1 | 2007 | 14 | 0.260 |
Why?
|
| Mice | 12 | 2020 | 12702 | 0.260 |
Why?
|
| Models, Biological | 1 | 2015 | 1805 | 0.260 |
Why?
|
| Ibuprofen | 1 | 2007 | 35 | 0.260 |
Why?
|
| Policy Making | 2 | 2017 | 64 | 0.260 |
Why?
|
| Neoplasm Staging | 3 | 2025 | 2081 | 0.250 |
Why?
|
| Disease Models, Animal | 3 | 2011 | 2573 | 0.240 |
Why?
|
| Nutrition Surveys | 2 | 2024 | 139 | 0.240 |
Why?
|
| Neoplasms | 4 | 2021 | 3340 | 0.230 |
Why?
|
| Health Policy | 2 | 2017 | 216 | 0.230 |
Why?
|
| World Health Organization | 1 | 2025 | 125 | 0.220 |
Why?
|
| Pain | 1 | 2007 | 417 | 0.220 |
Why?
|
| Sexism | 1 | 2025 | 64 | 0.210 |
Why?
|
| Signal Transduction | 2 | 2015 | 3623 | 0.210 |
Why?
|
| Triticum | 1 | 2024 | 24 | 0.210 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2025 | 105 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 5 | 2014 | 583 | 0.200 |
Why?
|
| Diet | 2 | 2024 | 469 | 0.200 |
Why?
|
| Mice, Nude | 4 | 2020 | 830 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1289 | 0.190 |
Why?
|
| Animals | 13 | 2020 | 28907 | 0.190 |
Why?
|
| Cell Proliferation | 5 | 2020 | 1790 | 0.190 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 1089 | 0.180 |
Why?
|
| Drinking Water | 1 | 2023 | 80 | 0.180 |
Why?
|
| Aged | 8 | 2025 | 21737 | 0.180 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2020 | 25 | 0.180 |
Why?
|
| Faculty, Medical | 1 | 2023 | 193 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 1 | 2025 | 478 | 0.170 |
Why?
|
| Blotting, Western | 2 | 2014 | 779 | 0.160 |
Why?
|
| Double-Blind Method | 1 | 2025 | 1781 | 0.160 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 1193 | 0.160 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2021 | 185 | 0.150 |
Why?
|
| Tumor Burden | 3 | 2020 | 330 | 0.150 |
Why?
|
| Retinal Dehydrogenase | 1 | 2019 | 8 | 0.150 |
Why?
|
| Telephone | 1 | 2019 | 43 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 557 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 665 | 0.140 |
Why?
|
| Stromal Cells | 1 | 2019 | 153 | 0.140 |
Why?
|
| Genetic Counseling | 1 | 2019 | 110 | 0.140 |
Why?
|
| Sphingosine | 1 | 2019 | 73 | 0.140 |
Why?
|
| Lysophospholipids | 1 | 2019 | 67 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 1110 | 0.140 |
Why?
|
| Middle Aged | 8 | 2025 | 29388 | 0.140 |
Why?
|
| Sodium, Dietary | 1 | 2017 | 9 | 0.130 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2017 | 11 | 0.130 |
Why?
|
| Carcinogenesis | 1 | 2019 | 242 | 0.130 |
Why?
|
| Adult | 8 | 2025 | 29496 | 0.130 |
Why?
|
| Apoptosis | 3 | 2014 | 1752 | 0.130 |
Why?
|
| Cell Survival | 2 | 2020 | 1016 | 0.130 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 36 | 0.130 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 189 | 0.130 |
Why?
|
| Fallopian Tubes | 1 | 2017 | 49 | 0.120 |
Why?
|
| Chemoprevention | 1 | 2017 | 93 | 0.120 |
Why?
|
| Omentum | 2 | 2020 | 69 | 0.120 |
Why?
|
| Internet | 1 | 2019 | 358 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 3 | 2019 | 1028 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 321 | 0.120 |
Why?
|
| Carbon | 1 | 2016 | 99 | 0.120 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 642 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2025 | 1121 | 0.120 |
Why?
|
| Phenformin | 1 | 2015 | 6 | 0.120 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2015 | 15 | 0.120 |
Why?
|
| Aspirin | 1 | 2017 | 168 | 0.120 |
Why?
|
| Male | 8 | 2025 | 47043 | 0.110 |
Why?
|
| Glucose | 2 | 2016 | 704 | 0.110 |
Why?
|
| Ascites | 1 | 2015 | 55 | 0.110 |
Why?
|
| Lactic Acid | 1 | 2015 | 95 | 0.110 |
Why?
|
| Cell Movement | 1 | 2019 | 815 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2016 | 10964 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2019 | 594 | 0.110 |
Why?
|
| Lovastatin | 1 | 2014 | 28 | 0.110 |
Why?
|
| Survival Rate | 2 | 2016 | 2043 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 159 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 532 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 212 | 0.100 |
Why?
|
| Argentina | 2 | 2024 | 15 | 0.100 |
Why?
|
| Fibronectins | 1 | 2014 | 104 | 0.100 |
Why?
|
| Drug Synergism | 1 | 2014 | 317 | 0.100 |
Why?
|
| United States | 2 | 2025 | 8220 | 0.100 |
Why?
|
| Likelihood Functions | 1 | 2014 | 258 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 552 | 0.100 |
Why?
|
| Child | 5 | 2024 | 7696 | 0.100 |
Why?
|
| Mass Screening | 1 | 2018 | 748 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 889 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 602 | 0.090 |
Why?
|
| Mitochondria | 1 | 2016 | 647 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 3607 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2017 | 9688 | 0.090 |
Why?
|
| Estrogen Antagonists | 1 | 2011 | 47 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2015 | 489 | 0.090 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 83 | 0.090 |
Why?
|
| Anoikis | 1 | 2011 | 7 | 0.090 |
Why?
|
| Coculture Techniques | 3 | 2020 | 175 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2011 | 239 | 0.080 |
Why?
|
| Anilides | 1 | 2011 | 50 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 82 | 0.080 |
Why?
|
| Mice, Transgenic | 2 | 2011 | 1605 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 2555 | 0.080 |
Why?
|
| Prognosis | 2 | 2016 | 4115 | 0.080 |
Why?
|
| Infant | 3 | 2023 | 3332 | 0.080 |
Why?
|
| Quinolines | 1 | 2011 | 97 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2024 | 4005 | 0.080 |
Why?
|
| Adipose Tissue | 1 | 2013 | 280 | 0.080 |
Why?
|
| Ovary | 1 | 2011 | 260 | 0.080 |
Why?
|
| fas Receptor | 1 | 2010 | 73 | 0.080 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 195 | 0.080 |
Why?
|
| Gonadotropins | 1 | 2009 | 32 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 199 | 0.070 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2009 | 48 | 0.070 |
Why?
|
| Integrases | 1 | 2009 | 68 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 291 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2009 | 152 | 0.070 |
Why?
|
| Estrogens | 1 | 2009 | 202 | 0.070 |
Why?
|
| Mutation | 2 | 2018 | 4396 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 4029 | 0.070 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 185 | 0.070 |
Why?
|
| Abortion, Therapeutic | 1 | 2007 | 11 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2014 | 3210 | 0.060 |
Why?
|
| Chicago | 1 | 2012 | 1517 | 0.060 |
Why?
|
| Analgesics | 1 | 2007 | 131 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3607 | 0.060 |
Why?
|
| Young Adult | 3 | 2024 | 7529 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 1764 | 0.060 |
Why?
|
| Adolescent | 3 | 2024 | 10096 | 0.060 |
Why?
|
| Lipid Metabolism | 2 | 2020 | 221 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2009 | 2206 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 3273 | 0.050 |
Why?
|
| Fast Foods | 1 | 2023 | 5 | 0.050 |
Why?
|
| Food Handling | 1 | 2023 | 8 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2024 | 76 | 0.050 |
Why?
|
| Drinking | 1 | 2023 | 34 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2024 | 246 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2024 | 187 | 0.050 |
Why?
|
| Water Supply | 1 | 2023 | 65 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2024 | 175 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 339 | 0.040 |
Why?
|
| Recommended Dietary Allowances | 1 | 2021 | 3 | 0.040 |
Why?
|
| Diet Records | 1 | 2021 | 20 | 0.040 |
Why?
|
| Diethylstilbestrol | 1 | 2021 | 121 | 0.040 |
Why?
|
| Hip Fractures | 1 | 2021 | 55 | 0.040 |
Why?
|
| Succinate-CoA Ligases | 1 | 2019 | 2 | 0.040 |
Why?
|
| Prolyl Hydroxylases | 1 | 2019 | 4 | 0.040 |
Why?
|
| Developing Countries | 1 | 2021 | 101 | 0.040 |
Why?
|
| Eating | 1 | 2021 | 164 | 0.040 |
Why?
|
| Protein Array Analysis | 1 | 2020 | 53 | 0.040 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 63 | 0.040 |
Why?
|
| Risk | 1 | 2021 | 660 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2019 | 4808 | 0.040 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2020 | 31 | 0.040 |
Why?
|
| Heterografts | 1 | 2020 | 121 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 188 | 0.040 |
Why?
|
| Metabolomics | 1 | 2020 | 106 | 0.040 |
Why?
|
| AC133 Antigen | 1 | 2019 | 10 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 256 | 0.040 |
Why?
|
| Bone Density | 1 | 2021 | 248 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 61 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2020 | 160 | 0.040 |
Why?
|
| Poverty | 1 | 2021 | 214 | 0.040 |
Why?
|
| Carboplatin | 1 | 2020 | 331 | 0.040 |
Why?
|
| 5-Methylcytosine | 1 | 2020 | 134 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 529 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 2051 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2017 | 21 | 0.030 |
Why?
|
| Proteomics | 1 | 2020 | 278 | 0.030 |
Why?
|
| Education | 1 | 2017 | 59 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2020 | 743 | 0.030 |
Why?
|
| Incidence | 1 | 2021 | 1783 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 551 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2021 | 1146 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2021 | 1094 | 0.030 |
Why?
|
| Metabolome | 1 | 2016 | 70 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2016 | 374 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2020 | 730 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 666 | 0.030 |
Why?
|
| Mammography | 1 | 2018 | 504 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1224 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2021 | 2535 | 0.030 |
Why?
|
| Integrins | 1 | 2014 | 81 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 94 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 423 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2014 | 420 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2014 | 259 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 564 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1946 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 400 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2010 | 21 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2010 | 48 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 257 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 674 | 0.020 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2010 | 60 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2010 | 137 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 518 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1609 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 639 | 0.020 |
Why?
|
| Obesity | 1 | 2013 | 1072 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2010 | 826 | 0.010 |
Why?
|